Stealth BioTherapeutics Case Study

Stealth BioTherapeutics used our real-time sterile manufacturing to enable a new route of drug administration.

Our Translational Pharmaceutics® platform was the cost-effective, rapid delivery solution that Stealth BioTherapeutics needed to accelerate their drug development program

Stealth BioTherapeutics is an innovative biopharmaceutical company based in Massachusetts, USA, focused on developing targeted therapies for diseases linked by a common aetiology of mitochondrial dysfunction. There are more than 270 inherited orphan mitochondrial diseases that are characterized by known genetic defects. Relatively recently, research has shown that mitochondrial dysfunction is associated with conditions including heart failure, kidney disease, age-related macular degeneration, cardiovascular and metabolic diseases, neurodegeneration and some musculoskeletal disorders.

Stealth BioTherapeutics was looking for a partner to reformulate a drug target, initially in the US, but found that option to be cumbersome in its approach to clinical manufacturing and timely potentially adding months onto their timeline. Hearing about Quotient Sciences which can offer on-site clinical manufacturing and a project design with a turnaround of 72 hours for pharmacokinetic (PK) and safety data, a site visit followed and within three days, Stealth BioTherapeutics accepted our proposal. After taking everything into account the manufacturing costs of a traditional CMO who creates multiple lots of clinical trial material that may never get used, our Translational Pharmaceutics® platform was the cost-effective option they needed.

Download our Case Study with Stealth BioTherapeutics

Learn more about how Quotient Sciences' experts helped Stealth BioTherapeutics with our integrated, rapid drug development capabilities.

"My first response was this is too good to be true, they can’t do that. We’ve been looking for this type of solution for years – it can’t be done. However, we made a site visit and, within three days, accepted the proposal... We had clinical data within weeks... reducing the overall timeline by half, if not more.”

- Deborah Gouveia, Vice President, Program and Alliance Management at Stealth BioTherapeutics

Stealth BioTherapeutics Case Study - Quotient Sciences

Contact our experts

Global, integrated expertise. Local drug development partner.
Accelelerate Your Program